西达本胺治疗外周T细胞淋巴瘤的效果和安全性分析  

Curative Effect and Safety of Chidamide in Treatment of Patients with Peripheral T-Cell Lymphoma

作　　者：王杰松[1] 何鸿鸣[1] 杨瑜[1] 林剑扬[1] 郑艳彬[1] 吴晖[1] 陈道光[1] 陈英[1] 陈宁斌[1] 邹思平[1] 陈秀容[1] 王畅 WANG Jie-song;HE Hong-ming;YANG Yu;LIN Jian-yang;ZHENG Yan-bin;WU Hui;CHEN Dao-guang;CHEN Ying;CHEN Ning-bin;ZOU Si-ping;CHEN Xiu-rong;WANG Chang(Department of Lymphoma and Head and Neck Oncology,Fujian Provincial Cancer Hospital,Fuzhou 350000,China)

机构地区：[1]福建省肿瘤医院淋巴瘤头颈部肿瘤内科,福州350000

出　　处：《解放军医药杂志》2018年第12期15-18,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：福建省自然科学基金资助项目(2015J01433)

摘　　要：目的探讨西达本胺对外周T细胞淋巴瘤(PTCL)的疗效和安全性。方法 2015年4月—2017年9月福建省肿瘤医院淋巴瘤头颈部肿瘤内科收治PTCL患者25例,行西达本胺单药或联合治疗;治疗4个周期后,评价近期疗效,并观察远期生存情况及治疗期间药物不良反应发生情况。结果本组单药治疗客观有效率为62. 50%。1年和2年无进展生存率分别为56. 25%和43. 75%,中位无进展生存期为11个月。联合治疗客观有效率为55. 56%,1年和2年无进展生存率分别为77. 78%和66. 67%,中位无进展生存期为15个月。单药和联合治疗近期有效患者2年无进展生存率和中位无进展生存期均明显优于近期无效患者(P <0. 05)。本组共发生45例次不良反应,且均可耐受。结论西达本胺治疗PTCL有较好效果,且耐受性较好。Objective To investigate curative effect and safety of Chidamide in treatment of patients with peripheral T-cell lymphoma(PTCL).Methods A total of 25 patients with PTCL admitted during April 2015 and September 2017 were treated with either Chidamide only or Chidamide combination therapy.After 4 cycles of treatment,short-term curative effect was evaluated,and conditions of long-term survival rate and incidence rate of adverse drug reactions during treatment were observed.Results The objective effective rate by only one drug was 62.50%.The 1-year and 2-years progression-free survival rates were 56.25%and 43.75%respectively,and the median progression-free survival time was 11 months.The objective effective rate of combination therapy was 55.56%.The 1-year and 2-years progression-free survival rates were 77.78%and 66.67%respectively,and the median progression-free survival time was 15 months.The 2-years progression-free survival rate and the median progression-free survival rate of patients with effective short-term curative effect by only one drug and combination therapy were significantly better than those of patients with ineffective short-term curative effect(P<0.05).Adverse reactions were found in 45 patients,and all patients could tolerate.Conclusion Chidamide is effective and can be tolerated in treatment of patients with peripheral T-cell lymphoma.

关 键 词：淋巴瘤 T细胞 外周 西达本胺 治疗结果 

分 类 号：R733.4[医药卫生—肿瘤]